14 results
ARS
2023 FY
TARS
Tarsus Pharmaceuticals Inc
26 Apr 24
Annual report to shareholders
4:27pm
our ability to recoup our investment in one or more product candidates, even if such product candidates obtain marketing approval. Failure to comply
ARS
2022 FY
TARS
Tarsus Pharmaceuticals Inc
26 Apr 23
Annual report to shareholders
4:08pm
are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one
10-K
gbo7ocd10bllnatv
31 Mar 21
Annual report
5:01pm
10-Q
0okzxlqhn4usf l4e
24 Nov 20
Quarterly report
9:27pm
424B4
9iatmbv5101sa4qa 7p
16 Oct 20
Prospectus supplement with pricing info
4:40pm
S-1/A
g7cwa5wvdg3hts
9 Oct 20
IPO registration (amended)
5:16pm
S-1
03cnt jjm
25 Sep 20
IPO registration
5:25pm
DRS/A
y1nih
14 Sep 20
Draft registration statement (amended)
12:00am
DRS
0w80 3018
7 Aug 20
Draft registration statement
12:00am
- Prev
- 1
- Next